Comparative Pharmacology
Head-to-head clinical analysis: ALLERNAZE versus CLARINEX D 24 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALLERNAZE versus CLARINEX D 24 HOUR.
ALLERNAZE vs CLARINEX D 24 HOUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at histamine H1 receptors, preventing histamine-mediated symptoms such as itching, sneezing, and vasodilation.
Desloratadine is a long-acting tricyclic histamine antagonist with selective peripheral H1-receptor antagonist activity. Loratadine is a long-acting antihistamine that selectively antagonizes peripheral H1-receptors.
5 mg orally once daily at bedtime, maximum 10 mg per day.
1 tablet (5 mg desloratadine/120 mg pseudoephedrine) orally once daily
None Documented
None Documented
Terminal elimination half-life is 12-15 hours. Clinical context: Allows for twice-daily dosing in allergic rhinitis; steady-state reached in 2-3 days.
Desloratadine: terminal t1/2 27 hours (range 20-50h) supporting once-daily dosing. Pseudoephedrine: t1/2 5-8 hours (up to 16h in alkaline urine).
Primarily renal (70-80% as unchanged drug and metabolites), with approximately 5-10% biliary/fecal elimination.
Desloratadine: ~87% excreted as metabolites (41% urine, 43% feces), <2% unchanged. Pseudoephedrine: ~70-90% excreted unchanged in urine.
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination